Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia Journal Article


Authors: Klimek, V. M.; Dolezal, E. K.; Smith, L.; Soff, G.; Nimer, S. D.
Article Title: Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia
Abstract: Sodium salicylate is an inexpensive, readily available anti-inflammatory agent which inhibits NF-κB in in vitro models. We examined whether it was possible to safely achieve and maintain salicylate levels known to inhibit NF-κB in vitro in 11 patients with MDS or AML taking sodium salicylate. Most patients achieved the target blood salicylate level (20-30. mg/dL) with acceptable toxicity, including reversible grade 1/2 elevations of hepatic transaminases (. n=. 4) and ototoxicity (. n=. 4). One patient had grade 3/4 elevations in AST/ALT. This study suggests that sodium salicylate may be safely combined with conventional chemotherapy regimens which are not associated with significant ototoxicity or hepatotoxicity. © 2011 Elsevier Ltd.
Keywords: adult; cancer chemotherapy; clinical article; controlled study; aged; aged, 80 and over; middle aged; acute granulocytic leukemia; leukemia, myeloid, acute; drug tolerability; neutropenia; dose response; drug dose reduction; drug efficacy; drug safety; drug withdrawal; side effect; outcome assessment; steady state; thrombocytopenia; tinnitus; immunoglobulin enhancer binding protein; in vitro study; drug effect; liver; myelodysplastic syndrome; anti-inflammatory agents, non-steroidal; nf-kappa b; thrombocyte count; clinical effectiveness; drug blood level; phase 1 clinical trial; hearing loss; myelodysplastic syndromes; ototoxicity; acute myelogenous leukemia; thrombocyte aggregation; platelet aggregation; sodium salicylate; nf-?b; salicylate sodium; balance impairment
Journal Title: Leukemia Research
Volume: 36
Issue: 5
ISSN: 0145-2126
Publisher: Elsevier Ltd  
Date Published: 2012-05-01
Start Page: 570
End Page: 574
Language: English
DOI: 10.1016/j.leukres.2011.10.023
PROVIDER: scopus
PUBMED: 22154022
DOI/URL:
Notes: --- - "Export Date: 2 April 2012" - "CODEN: LERED" - "Source: Scopus"
Altmetric
Citation Impact
MSK Authors
  1. Larry J Smith
    7 Smith
  2. Virginia Klimek
    123 Klimek
  3. Stephen D Nimer
    347 Nimer
  4. Gerald A Soff
    72 Soff